Pharma Capital

Advanced Oncotherapy passes another key milestone

The company has announced the final coupled cavity linac (CCL) module is ready for shipment to the Geneva testing facility
Office workers
AVO is developing a next-generation proton therapy system

Advanced Oncotherapy PLC (LON:AVO) has reached another milestone in the development of its first LIGHT system, a next-generation proton therapy unit.

It has announced the final coupled cavity linac (CCL) module is ready for shipment to the Geneva testing facility.

The CCL unit used to generate a beam capable of treating superficial tumours when integrated with all the other components.

READ: Advanced Oncotherapy on track to treat first LIGHT patient in 2020

It means the LIGHT system remains on track to produce its first proton beam capable of treating cancer in the third-quarter of next year.

"The successful manufacture, performance testing and now delivery of the CCLs are a major milestone in the technological development of the LIGHT system,” said AVO chief executive Nicolas Serandour.

“For the first time, we will now have all of the key high-speed accelerating modules for LIGHT in place in our Geneva site and with a great deal of the manufacturing risk behind us, we can focus on the integration and commissioning of the individual components.

“This development brings the reality of the world's first linear proton accelerator in the treatment of cancer much closer."

At 1.25pm, the shares were up 5.6% at 16.62p.

---adds share price---

View full AVO profile

Advanced Oncotherapy Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.